Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Search by expertise, name or affiliation
Edoxaban versus warfarin in patients with atrial fibrillation
ENGAGE AF-TIMI 48 Investigators
Icahn School of Medicine at Mount Sinai
Medicine
Medicine - Cardiology
Medicine - Endocrinology, Diabetes and Bone Disease
Research output
:
Contribution to journal
›
Article
›
peer-review
4248
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Edoxaban versus warfarin in patients with atrial fibrillation'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Warfarin
100%
Atrial Fibrillation
100%
Edoxaban
100%
Hazard Ratio
83%
Confidence Interval
83%
High Dose
25%
Systemic Embolism
25%
Non-inferiority
25%
Major Bleeding
16%
Once-daily Regimen
16%
Median Time
8%
Intention-to-treat Analysis
8%
High Risk
8%
Treatment Duration
8%
Low Dose Rate
8%
Bleeding
8%
Long-term Efficacy
8%
Time in Therapeutic Range
8%
Long-term Safety
8%
Randomized Double-blind
8%
Stroke Prevention
8%
Death Rate
8%
Double Dummy
8%
Oral Factor Xa Inhibitors
8%
Direct Oral
8%
Antithrombotic Effect
8%
Pharma
8%
Daiichi
8%
ENGAGE AF-TIMI 48
8%
Pharmacology, Toxicology and Pharmaceutical Science
Atrial Fibrillation
100%
Warfarin
100%
Edoxaban
100%
Bleeding
25%
Cerebrovascular Accident
25%
Anticoagulant Agent
8%
Blood Clotting Factor 10a Inhibitor
8%